van Oosterhout Joep J G, Brown Lillian, Weigel Ralf, Kumwenda Johnstone J, Mzinganjira Dalitso, Saukila Nasinuku, Mhango Brian, Hartung Thomas, Phiri Sam, Hosseinipour Mina C
Department of Medicine, University of Malawi College of Medicine, Blantyre, Malawi.
Trop Med Int Health. 2009 Aug;14(8):856-61. doi: 10.1111/j.1365-3156.2009.02309.x. Epub 2009 Jun 22.
In antiretroviral therapy (ART) scale-up programmes in sub-Saharan Africa viral load monitoring is not recommended. We wanted to study the impact of only using clinical and immunological monitoring on the diagnosis of virological ART failure under routine circumstances.
Clinicians in two urban ART clinics in Malawi used clinical and immunological monitoring to identify adult patients for switching to second-line ART. If patients met clinical and/or immunological failure criteria of WHO guidelines and had a viral load <400 copies/ml there was misclassification of virological ART failure.
Between January 2006 and July 2007, we identified 155 patients with WHO criteria for immunological and/or clinical failure. Virological ART failure had been misclassified in 66 (43%) patients. Misclassification was significantly higher in patients meeting clinical failure criteria (57%) than in those with immunological criteria (30%). On multivariate analysis, misclassification was associated with being on ART <2 years [OR = 7.42 (2.63, 20.95)] and CD4 > 200 cells/microl [OR = 5.03 (2.05, 12.34)]. Active tuberculosis and Kaposi's sarcoma were the most common conditions causing misclassification of virological ART failure.
Misclassification of virological ART failure occurs frequently using WHO clinical and immunological criteria of ART failure for poor settings. A viral load test confirming virological ART failure is therefore advised to avoid unnecessary switching to second-line regimens.
在撒哈拉以南非洲的抗逆转录病毒治疗(ART)扩大项目中,不建议进行病毒载量监测。我们希望研究在常规情况下仅使用临床和免疫学监测对ART病毒学治疗失败诊断的影响。
马拉维两家城市ART诊所的临床医生使用临床和免疫学监测来确定需要换用二线ART的成年患者。如果患者符合WHO指南的临床和/或免疫学失败标准且病毒载量<400拷贝/毫升,则存在病毒学ART治疗失败的错误分类。
在2006年1月至2007年7月期间,我们确定了155例符合WHO免疫学和/或临床失败标准的患者。66例(43%)患者的病毒学ART治疗失败被错误分类。符合临床失败标准的患者错误分类率(57%)显著高于符合免疫学标准的患者(30%)。多变量分析显示,错误分类与接受ART治疗<2年[比值比(OR)=7.42(2.63,20.95)]和CD4>200细胞/微升[OR=5.03(2.05,12.34)]有关。活动性结核病和卡波西肉瘤是导致病毒学ART治疗失败错误分类的最常见情况。
在资源匮乏地区,使用WHO的ART治疗失败临床和免疫学标准时,病毒学ART治疗失败的错误分类经常发生。因此,建议进行病毒载量检测以确认病毒学ART治疗失败,避免不必要地换用二线治疗方案。